Biopharma Quarterly Dealmaking Statistics, Q1 2015
A look at financing, M&A, and alliance activity January–March 2015
Executive Summary
Biopharma financing reached $15.1 billion, with record-breaking FOPO dollar volume making up close to $10 billion of the total; AbbVie topped the $66.5 billion M&A activity with its $20 billion buy of Pharmacyclics; and gastroenterology was one of the most highly partnered therapeutic areas.
You may also be interested in...
Novartis Aims To Leap-Frog Into Next Immuno-Oncology Wave With Aduro
Novartis hopes its multi-year deal with Aduro Biotech to develop molecules to unlock dormant immune cells by targeting and activating a central signaling pathway called STING will allow it to make up for lost time and catch “the next wave” in immuno-oncology.
Valeant To Buy Dendreon’s Never-Was Cancer Vaccine Provenge
The dealmaking machine has proposed buying Dendreon’s assets, including prostate cancer immunotherapy Provenge, through a bankruptcy rummage sale.
Depomed To Make Treasure Out of J&J Trash With Nucynta Buy
Depomed is leveraging all its value to bet on a drug that was virtually ignored by its big pharma owner with its billion-dollar buy of Janssen’s Nucynta.